Accelerating Drug Discovery for FTD
Through this program, AFTD, in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), seeks to advance and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs.
Current funding priorities for this program include:
- Lead optimization of novel disease-modifying compounds (e.g., medicinal chemistry refinement, in vitro ADME)
- Testing of novel compounds, biologics, or repurposed drugs in relevant animal models (e.g., in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, preliminary rodent tolerability studies)
Note: This program is not currently funding:
- Target identification/validation
- Assay development
- High-throughput/high-content screening
- Duration: 1 year, with the possibility of follow-on funding.
- Average award amount (USD): $100,000 – $150,000.
- Application of funds: Funding through this program supports approved personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials.
Funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless pre-approved under special circumstances).
- Additional Information: Visit the ADDF website for additional information.
Who can apply?
U.S. and international investigators working at:
- Academic medical centers and universities; nonprofits
- Biotechnology companies (existing companies or new spinouts) that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones.
Academic-industry partnerships are strongly encouraged.
Timeline — 2018 Awards
- May 2018: RFP posted
- July 13, 2018: LOIs due
- August 10, 2018: Full invited applications due
- December 2018-January 2019: Notification of awards
Download the 2018 Drug Discovery Request for Proposals.
LOIs are reviewed on a rolling basis and can be submitted at any time prior to the deadline.
Applications are reviewed by ADDF and an external Scientific Review Committee, including members of the AFTD Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF’s Business Advisory Board.
For program-related inquiries, please contact:
- Lauren Friedman, PhD, Acting Director for Scientific Affairs, ADDF
Phone: 212-901-8017 / Email: email@example.com
- Nadine Tatton, PhD, Scientific Director, AFTD
Phone: 267-758-8644 / Email: firstname.lastname@example.org
For application submission inquiries, please contact:
- Grants and Mission-Related Investments Team, ADDF
Phone: 212-901-8019 / Email: email@example.com